The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment. To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR). Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients. The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of BLCA.
25 February 2025 in Cancer Immunology, Immunotherapy
Background The pathogenesis and progression of renal cell carcinoma (RCC) involve complex programmed cell death (PCD) processes. As the powerhouse of the cell, mitochondria can influence cell death mechanisms. However, the prognostic significance of the interplay between mitochondrial function (MF) and PCD remains unclear. Methods We collected sets of genes related to PCD and MF. Using a powerful machine learning algorithm framework, we investigated the relationship between MF and PCD in different cohorts of patients and developed a machine learning-derived prognostic signature (mpMLDPS) related to MF and PCD. Finally, the most appropriate prognostic markers for RCC were screened by survival analysis and clinical correlation analysis, and the effects on renal cancer cells were analysed in vitro. Results mpMLDPS was significantly correlated with the prognosis of RCC patients, and the prognosis was worse in the high mpMLDPS group, and this result was also validated in external independent cohorts. There were associations between mpMLDPS and immune checkpoints, tumour microenvironment, somatic mutations, and drug sensitivity. Finally, a novel RCC prognostic marker PIF1 was identified in model genes. The knockdown of PIF1 in vitro inhibited the progression of renal carcinoma cells. Conclusion mpMLDPS has great potential to serve as a reliable clinical signature to improve the accuracy and reliability of prognostic assessment in RCC patients, thereby choosing the appropriate therapeutic regimen in clinical practice. PIF1 is also expected to be a novel target for the clinical treatment of RCC.
1 January 2024 in International Journal of Medical Sciences
Background: Protein information is often replaced by RNA data in studies to understand cancer-related biological processes or molecular functions, and proteins of prognostic significance in Kidney clear cell carcinoma (KIRC) remain to be mined.
24 March 2026 in European Journal of Medical Research
To investigate the effects of unilateral ureteral obstruction on renal pelvic peristalsis and pacemaker cells in neonatal rats. Thirty-six 2-day-old Spragu
5 August 2026 in International Journal of Surgery Case Reports
Introduction and importance: Renal small-cell neuroendocrine carcinoma (renal SCNEC) is an exceedingly rare and highly aggressive tumor of the urinary system, originating from peptidergic neurons or neuroendocrine cells. The disease often presents with insidious clinical symptoms and lacks specific imaging features, which can delay diagnosis and predispose to distant metastases. Here, we report a case of renal SCNEC and describe its diagnosis, treatment, and outcomes, aiming to enhance clinical understanding and management of this rare condition. Case presentation: We report the case of a 64-year-old man who presented with left-sided flank pain without hematuria. Imaging studies revealed a mass in the left kidney. Percutaneous biopsy and immunohistochemical analysis confirmed the diagnosis of SCNEC. The patient received two cycles of neoadjuvant chemotherapy consisting of cisplatin and etoposide, followed by laparoscopic radical nephrectomy. Postoperative chemotherapy was administered according to the planned regimen. During 16 months of follow-up, no evidence of recurrence was observed. Discussion: Prompt recognition and diagnosis of renal SCNEC are crucial to prevent misdiagnosis and delayed treatment. Diagnosis relies on histopathology, immunohistochemistry, and careful evaluation of common metastatic sites, including lymph nodes, liver, and bones. Treatment should be individualized based on disease stage and the patient’s condition; for locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may be considered as part of a multimodal treatment strategy in selected patients. Given the rarity of this tumor, multidisciplinary collaboration and evidence-based research are essential to optimize management and establish standardized treatment guidelines. Conclusion: For patients with locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may provide a therapeutic option after multidisciplinary evaluation.
The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment.To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR).Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients.The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of bladder cancer.